This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Phosphoinositide 3-kinase-α (PI3Kα); mammalian target of rapamycin (mTOR; FRAP; RAFT1)	Mouse studies identified a benzothiazole-based dual inhibitor of PI3Kα and mTOR that could help treat cancer. In three mouse models of human xenograft cancers, the dual inhibitor decreased tumor growth compared with vehicle control and had ED_{50} values of 0.26–0.63 mg/kg. Next steps could include developing and evaluating optimized PI3Kα and mTOR dual inhibitors in cancer models. At least four companies have dual mTOR and PI3K inhibitors in Phase I/II testing or earlier to treat cancer. *SciBX* 4(11); doi:10.1038/scibx.2011.308 Published online March 17, 2011	Patented; licensing status unavailable	D'Angelo, N.D. *et al. J. Med. Chem.*; published online Feb. 18, 2011; doi:10.1021/jm1014605 **Contact:** Noel D. D'Angelo, Amgen Inc., Thousand Oaks, Calif. e-mail: dangelo@amgen.com